---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-254476"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2026-06-03T10:01:45+00:00"
generated_at: "2026-06-03T10:12:00.107827+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IDEAYA announces clinical collaboration with Roche for PRMT5 + pan-RAS combo in MTAP-deleted PDAC

## Summary
- IDE892 (PRMT5 inhibitor) to be combined with Roche's RG6505 (pan-RAS inhibitor) in MTAP-deleted, RAS-mutant pancreatic cancer.
- IDEAYA will sponsor the Phase 1 combination trial; Roche will supply RG6505.
- MTAP deletion occurs in up to 40% of PDAC; almost all such cases have co-occurring RAS mutations.
- Both companies retain full commercial rights to their compounds; joint governance oversees the study.
- Triplet combination with IDE397 (MAT2A inhibitor) may be evaluated with joint approval.

## SEC filing metadata
- accession: 0001193125-26-254476
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2026-06-03T10:01:45+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312526254476/0001193125-26-254476-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312526254476/d53214d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-254476
- JSON: https://secwatch.observer/filing/0001193125-26-254476.json
- Plain text: https://secwatch.observer/filing/0001193125-26-254476.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.